NASDAQ · EYEN
Healthcare · Biotechnology
$7.56
Up+$0.29 (+3.99%)
Updated Sep 11, 2026, 1:25 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
EYEN does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning EYEN.
EYEN research
Company profile and research snapshot.
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 21, 2025 | HC Wainwright & Co. | Neutral | — |
| Feb 6, 2025 | HC Wainwright & Co. | Neutral | — |
| Nov 18, 2024 | Ladenburg Thalmann | Neutral | — |
| Nov 18, 2024 | HC Wainwright & Co. | Neutral | — |
| Nov 15, 2024 | Brookline Capital | Hold | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Feb 24, 2025
Eyenovia, Inc. has announced an amendment to its senior secured convertible debt, deferring interest and principal payments through September 2025. This provides financial flexibility as the company evaluates strategic alternatives to maximize shareholder value.
GlobeNewswire Inc. · Jan 15, 2025
Eyenovia, an ophthalmic technology company, announced that leading proxy advisory firms ISS and Glass Lewis have recommended that Eyenovia stockholders vote in favor of a proposed reverse stock split at the upcoming special meeting. The reverse stock split is intended to enable Eyenovia to regain compliance with Nasdaq's Minimum Bid Price Requirement and maintain its Nasdaq listing.
GlobeNewswire Inc. · Jan 6, 2025
Eyenovia, an ophthalmic technology company, has engaged Chardan as its financial advisor to evaluate strategic alternatives, including a potential business combination, sale, or reverse merger. The company continues to progress the development of its Optejet device, exploring options for both consumer and drug-device combination products.
GlobeNewswire Inc. · Dec 6, 2024
Eyenovia, Inc. announced a $1.9 million registered direct offering, with the proceeds to be used for working capital, repayment of debt, and advancement of its Optejet device and commercialization activities.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EYEN.
No results
No recent SID articles mention EYEN.
